ACSL3 and cancer: In addition, OA also failed to protect ACSL3-deficient cancer cells from erastin (or RSL3)-induced lipid ROS elevation and a decrease in the GSH/GSSG ratio (Fig. 5C, D and Supplementary Fig. S4C-E).